Clinical implications of converting stable haemodialysis patients from subcutaneous to intravenous administration of darbepoetin alfa | Zendy

Michael Aarup | Zendy; Julie Bryndum | Zendy; Hans Dieperink | Zendy; Preben Joffe | Zendy

Open Access

Clinical implications of converting stable haemodialysis patients from subcutaneous to intravenous administration of darbepoetin alfa

Author(s) -

Michael Aarup,

Julie Bryndum,

Hans Dieperink,

Preben Joffe

Publication year - 2006

Publication title -

nephrology dialysis transplantation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.654

H-Index - 168

eISSN - 1460-2385

pISSN - 0931-0509

DOI - 10.1093/ndt/gfk048

Subject(s) - darbepoetin alfa , medicine , clinical endpoint , confidence interval , crossover study , population , epoetin alfa , randomized controlled trial , statistical significance , surgery , erythropoietin , alternative medicine , environmental health , pathology , placebo

The erythropoiesis-stimulating protein darbepoetin alfa (Aranesp) can be given intravenously (i.v.) or subcutaneously (s.c.). Despite a s.c. bioavailability of only 37%, darbepoetin alfa i.v. or s.c. dose requirements were comparable in previous studies designed to evaluate other aspects of anaemia treatment. The present study was designed to compare i.v. vs s.c. dose requirements.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research